You think a lot of upside is priced in at a $200m MC? Based on what metrics? Keen to understand.
I can’t see how a $3b per annum (minimum) market opportunity, with very little to no competition and (if granted) the backing of the FDA to grant early approval, would be valued at approx 3% with a 95-97% discount for risk that close to a green light. It just wouldn’t happen.
an $600m MC would make more sense in P2 IMO.
You think a lot of upside is priced in at a $200m MC? Based on...
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $86.90M | |||
| Open | High | Low | Value | Volume |
| 22.0¢ | 22.0¢ | 20.0¢ | $191.1K | 906.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1300 | 21.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 22.0¢ | 9563 | 1 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
21.0¢ |
Change
0.000 ( 6.67 %) |
||||
| Open | High | Low | Volume | ||
| 22.0¢ | 22.5¢ | 20.5¢ | 533029 | ||
| Last updated 15.54pm 03/05/2024 ? | |||||
| PAA (ASX) Chart |